Investment Thesis
Alnylam demonstrates exceptional financial momentum with 65.2% revenue growth, transformative profitability improvements (net income +212.8% YoY), and strong cash generation (FCF of $465.4M). The company exhibits solid financial health with a current ratio of 2.76x, manageable leverage at 0.86x debt-to-equity, and robust interest coverage of 14.2x, positioning it well for sustained growth and operational flexibility.
Strengths
- Explosive revenue growth of 65.2% YoY indicating strong market traction and demand for pipeline products
- Outstanding earnings leverage with net income up 212.8% YoY and net margin of 8.4%, demonstrating significant operational leverage
- Healthy balance sheet with $1.7B cash, current ratio of 2.76x, and manageable debt-to-equity ratio of 0.86x
- Strong free cash flow generation of $465.4M with 12.5% FCF margin supporting dividend potential and R&D investments
- Superior liquidity metrics with quick ratio of 2.71x indicating ability to meet short-term obligations
- Exceptional ROE of 39.8% reflecting highly efficient capital deployment
Risks
- Heavy reliance on pharmaceutical revenue with limited gross margin visibility in disclosed data
- Significant insider activity (27 Form 4 filings in 90 days) warrants monitoring for potential concern signals
- Operating margin of 13.5% compressed relative to net margin of 8.4% suggests elevated non-operating expenses or tax burden
- Long-term debt of $677.7M requires ongoing servicing despite strong cash flow generation
- Pharmaceutical sector exposure to regulatory changes, patent cliffs, and competitive pressures
Key Metrics to Watch
- Revenue growth sustainability and pipeline approval status
- Gross margin trends and product mix evolution
- Free cash flow consistency and cash conversion rate
- Debt reduction trajectory and leverage ratios
- Operating expense management and margin expansion potential
- R&D spending efficiency and pipeline advancement
Financial Metrics
Revenue
3.7B
Net Income
313.7M
EPS (Diluted)
$2.33
Free Cash Flow
465.4M
Total Assets
5.0B
Cash
1.7B
Profitability Ratios
Gross Margin
N/A
Operating Margin
13.5%
Net Margin
8.4%
ROE
39.8%
ROA
6.3%
FCF Margin
12.5%
Balance Sheet & Liquidity
Current Ratio
2.76x
Quick Ratio
2.71x
Debt/Equity
0.86x
Debt/Assets
84.1%
Interest Coverage
14.23x
Long-term Debt
677.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T18:05:31.814525 |
Data as of: 2025-12-31 |
Powered by Claude AI